More intriguingly, in vivo studies using subcutaneous (SC) and intraperitoneal (IP) xenograft models indicated that RAD51 promoter-mediated transcriptional targeting enabled cancer diagnosis and treatment when delivered with nanoparticles19. This evidence concerns the gene RAD51 and cancer.